Epitomee Medical Ltd (EPIT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Epitomee Medical Ltd (EPIT) has a cash flow conversion efficiency ratio of -0.416x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (ILA-12.78 Million ≈ $-34.27K USD) by net assets (ILA30.72 Million ≈ $82.35K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is Epitomee Medical Ltd worth for the company's overall valuation and market capitalisation.
Epitomee Medical Ltd - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Epitomee Medical Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Epitomee Medical Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Epitomee Medical Ltd ranked by their cash flow conversion efficiency. Explore Epitomee Medical Ltd (EPIT) cash earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Atlantaa Limited
NSE:ATLANTAA
|
-0.073x |
|
Dacome International Ltd
TWO:9960
|
0.022x |
|
Malayan United Industries Bhd
KLSE:3891
|
0.379x |
|
Prestige Wealth Inc.
NASDAQ:AURE
|
-0.001x |
|
Level Biotechnology
TWO:3118
|
0.021x |
|
Elektrocieplownia Bedzin
WAR:BDZ
|
0.159x |
|
Jet2 PLC
LSE:JET2
|
0.331x |
|
Deliveroo Holdings PLC
LSE:ROO
|
0.239x |
Annual Cash Flow Conversion Efficiency for Epitomee Medical Ltd (2019–2024)
The table below shows the annual cash flow conversion efficiency of Epitomee Medical Ltd from 2019 to 2024. View latest Epitomee Medical Ltd stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ILA33.95 Million ≈ $91.02K |
ILA-8.29 Million ≈ $-22.23K |
-0.244x | -7.30% |
| 2023-12-31 | ILA34.80 Million ≈ $93.30K |
ILA-7.92 Million ≈ $-21.24K |
-0.228x | +4.69% |
| 2022-12-31 | ILA39.45 Million ≈ $105.75K |
ILA-9.42 Million ≈ $-25.26K |
-0.239x | -121.08% |
| 2021-12-31 | ILA53.30 Million ≈ $142.89K |
ILA-5.76 Million ≈ $-15.44K |
-0.108x | -106.37% |
| 2020-12-31 | ILA3.98 Million ≈ $10.66K |
ILA6.75 Million ≈ $18.09K |
1.697x | +519.62% |
| 2019-12-31 | ILA6.89 Million ≈ $18.49K |
ILA-2.79 Million ≈ $-7.47K |
-0.404x | -- |
About Epitomee Medical Ltd
Epitomee Medical Ltd, a biomedical company, develops and commercializes ingestible therapeutic devices worldwide. It offers capsules, which are polymer-based scaffold for controlled delivery of therapies along the GI tract for weight management and biologics delivery. The company was incorporated in 2005 and is based in Caesarea, Israel.